In the last trading session, 4.33 million shares of the Virax Biolabs Group Ltd (NASDAQ:VRAX) were traded, and its beta was 1.88. Most recently the company’s share price was $1.11, and it changed around $0.23 or 26.64% from the last close, which brings the market valuation of the company to $4.82M. VRAX currently trades at a discount to its 52-week high of $9.00, offering almost -710.81% off that amount. The share price’s 52-week low was $0.60, which indicates that the current value has risen by an impressive 45.95% since then. We note from Virax Biolabs Group Ltd’s average daily trading volume that its 10-day average is 0.51 million shares, with the 3-month average coming to 197.56K.
Virax Biolabs Group Ltd stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended VRAX as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Virax Biolabs Group Ltd is expected to report earnings per share of 0 for the current quarter.
Virax Biolabs Group Ltd (NASDAQ:VRAX) trade information
Instantly VRAX has showed a green trend with a performance of 26.64% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.3400 on recent trading dayincreased the stock’s daily price by 17.16%. The company’s shares are currently down -50.67% year-to-date, but still up 13.79% over the last five days. On the other hand, Virax Biolabs Group Ltd (NASDAQ:VRAX) is -13.95% down in the 30-day period. We can see from the shorts that 0.14 million shares have been sold at a short interest cover period of 1.06 day(s).
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -52.25%.
VRAX Dividends
Virax Biolabs Group Ltd’s next quarterly earnings report is expected to be released in May.
Virax Biolabs Group Ltd (NASDAQ:VRAX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.63% of Virax Biolabs Group Ltd shares, and 6.72% of them are in the hands of institutional investors. The stock currently has a share float of 7.19%. Virax Biolabs Group Ltd stock is held by 9.0 institutions, with VIRTU FINANCIAL LLC being the largest institutional investor. By 2024-06-30, it held 1.3984% of the shares, which is about 28058.0 shares worth $33000.0.
HRT FINANCIAL LP, with 1.2795% or 25672.0 shares worth $29000.0 as of 2024-06-30, holds the second largest percentage of outstanding shares.
The former held 542.0 shares worth $601.0, making up 0.02% of all outstanding shares.